Glycocalyx Therapeutics AG

Glycocalyx Therapeutics AG is a pioneering biotechnology research company dedicated to developing transformative intratumoral pan-cancer therapies. Focusing on the tumor microenvironment, Glycocalyx Therapeutics AG aims to remove barriers and induce intratumoral immune architecture, facilitating effective full-circle immunotherapy. Their work involves the discovery, design, and engineering of catalytic immune effector systems.

Based in Basel, CH, Glycocalyx Therapeutics AG is committed to innovation in catalytic cancer immunotherapies. The company's research and development efforts are geared towards creating solutions that enhance the body's ability to fight cancer. Glycocalyx Therapeutics AG is poised to make significant contributions to the field of oncology through its cutting-edge approaches.

We invite the management of Glycocalyx Therapeutics AG to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work and attract new opportunities.